Clinical trials: Weight Bias
Obesity and Overweight
Efficacy and Safety of MET097 Once-Weekly in People With Overweight or Obesity
This study investigates the efficacy and safety of once weekly injectable MET097 in adult participants with obesity or overweight with weight-related comorbidities excluding T2D. This trial will last for a duration of 84 weeks.
- Trial name
- VESPER-4 (NCT07311850)
- Testing
- MET097
- Where
- 161 sites in United States, Bulgaria and 8 more
- Volunteers
- 3,578 people
- Sponsor
- Pfizer
Obesity, Overweight and/or Obesity
A Study to Learn About the Study Medicine (PF-08653944) in People With Obesity or Overweight and Type 2 Diabetes (T2D)
The purpose of this clinical study is to learn about the safety and effects of the study medicine to help adults with obesity or overweight and type 2 diabetes lose weight.
- Conditions
- Obesity, Overweight and/or Obesity, Overweight, Diabetes, Type 2
- Trial name
- NCT07400653
- Testing
- PF-08653944
- Where
- 180 sites in United States, Argentina and 9 more
- Volunteers
- 1,078 people
- Sponsor
- Pfizer
Obesity
A Study to Characterize Event Related Potential Markers of Attentional Bias Towards Words and Images of Food
GSK is planning to undertake two anti-obesity drug studies in the area of obesity. In addition to assessment by questionnaires, it would be of significant value to incorporate an objective non-interventional measure of cognitive…
- Trial name
- NCT01366508
- Testing
- High calorie lunch, Breakfast
- Where
- United Kingdom
- Volunteers
- 5 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline